RLFTF and RLFTY Related Headlines
Go Back- Relief Therapeutics Announces Positive Results from Pivotal Bioequivalence Study of RLF-OD032
- Relief Therapeutics Publishes 2025 Half-Year Report
- Relief Therapeutics Advances Publication of 2025 Half-Year Report
- Relief Therapeutics Announces Proposed Business Combination with NeuroX, Successor to MindMaze
- Relief Therapeutics Receives FDA Response to QIDP Request for RLF-TD011
- Relief Therapeutics Announces Results of Annual General Meeting
RLFTF and RLFTY Related Press Releases
Go Back- Relief Therapeutics Announces Positive Results from Pivotal Bioequivalence Study of RLF-OD032
- Relief Therapeutics Publishes 2025 Half-Year Report
- Relief Therapeutics Advances Publication of 2025 Half-Year Report
- Relief Therapeutics Announces Proposed Business Combination with NeuroX, Successor to MindMaze
- Relief Therapeutics Receives FDA Response to QIDP Request for RLF-TD011
- Relief Therapeutics Announces Results of Annual General Meeting
